Status:
COMPLETED
Rivastigmine For Methamphetamine Dependent Individuals
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborating Sponsors:
University of California, Los Angeles
Conditions:
Substance-Related Disorders
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Methamphetamine abuse has been steadily increasing over the past decade. Rivastigmine is a medication that may be helpful in treating methamphetamine dependence. The purpose of this study is to evalua...
Detailed Description
Methamphetamine is a powerful stimulant that affects the central nervous system. Chronic methamphetamine use often leads to psychotic behavior. Rivastigmine is an acetylcholinesterase inhibitor that i...
Eligibility Criteria
Inclusion
- Speaks English
- Not seeking treatment for methamphetamine dependence at study entry
- Meets DSM-IV criteria for methamphetamine abuse or dependence
- Smokes or intravenously uses methamphetamine
- Resting pulse between 50 and 90 beats per minute within 2 days prior to study entry
- Systolic blood pressure between 85 and 150 mmHg and diastolic blood pressure between 45 and 90 mmHg within 2 days prior to study entry
- Electrocardiogram demonstrating normal sinus rhythm, normal conduction, and no clinically significant arrhythmias
- Medical history and brief physical examination demonstrating no clinically significant contraindications for study participation
Exclusion
- History or evidence of seizures or brain injury
- Previous adverse reaction to methamphetamine
- Neurological or psychiatric disorders (e.g., psychosis, bipolar illness, or major depression)
- Organic brain disease or dementia
- History of any psychiatric disorder that requires ongoing treatment or that would make study compliance difficult
- History of suicide attempts within the 3 months prior to study entry
- Heart disease or high blood pressure
- Family history of early cardiovascular morbidity or mortality
- Untreated or unstable medical illness, including neuroendocrine, autoimmune, liver, kidney, or active infectious disease
- HIV infected
- AIDS-defining illness
- Currently taking antiretroviral medication
- Pregnant or breastfeeding
- Unwilling to use an adequate method of contraception for the duration of the study
- History of respiratory illness (e.g., asthma, chronic coughing, and wheezing)
- Currently using alpha or beta agonists, theophylline, or other sympathomimetics
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00158210
Start Date
May 1 2006
End Date
March 1 2007
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California - Los Angeles
Los Angeles, California, United States, 90024